MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

by | Dec 15, 2020

MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.



Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner